114.50 0.00 (0.00%)
After hours: 5:19PM EST
|Bid||109.10 x 1400|
|Ask||115.77 x 800|
|Day's Range||113.92 - 115.62|
|52 Week Range||73.69 - 119.84|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||263.22|
|Earnings Date||Feb 13, 2019|
|Forward Dividend & Yield||2.25 (1.98%)|
|1y Target Est||115.00|
How's Seattle Genetics Positioned? For fiscal 2018 and 2019, Seattle Genetics’ gross margins are expected at 88.54% and 88.58%, respectively, as compared with gross margins of 88.78% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Amgen (AMGN), Gilead Sciences (GILD), and Eli Lilly & Co (LLY) are expected at 85.83%, 84.81%, and 76.05%, respectively.
Seattle Genetics (SGEN) had generated net investment and other income of $82.22 million in the third quarter of 2017. In the third quarter of 2018, on the other hand, it incurred net investment and other loss of $21.87 million.
How's Seattle Genetics Positioned? Seattle Genetics (SGEN) is a biotechnology company with a focus on developing and bringing to market targeted therapies for cancer. Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.
Bristol-Myers (BMY) enters into a collaboration agreement with Vedanta Biosciences to study Opdivo clubbed with the latter's VE800 for treating patients with advanced or metastatic cancers.
The Zacks Analyst Blog Highlights: Eli Lilly, Anthem, BlackRock, CME Group and Southern Company
Costco stock and Okta stock lead five top stocks to watch. Investors shouldn't be making new buys, but these stocks could break out once conditions improve.
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) […]
U.S. equities have suffered from another bout of harrowing volatility this week as investors scramble to survive this bear market. The Dow Jones Industrial Average is threatening to fall below its multi-month support level to return to lows not seen since the beginning of the year. If those February lows are violated, watch for a possible reversal of much of the 2017 Trump tax cut rally.
Health-care stocks have found new life as markets crater. UnitedHealth UNH and Eli Lilly LLY roared to record highs on Tuesday, while Pfizer PFE and Merck MRK moved to their highest levels since 2001, although they were all down at least 1 percent in Thursday's premarket. Mark Newton , technical analyst at Newton Advisors, said Tuesday the overall health-care trade still looks like a solid play.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.
With the announced sale of its animal health division, Bayer became the latest pharmaceutical company to reverse this decade-long M&A binge.
Project to focus on preclinical and clinical research with cyclin dependent kinase (CDK)4 & 6 inhibitors PLYMOUTH MEETING, Pa. and INDIANAPOLIS , Dec. 3, 2018 /PRNewswire/ -- The National Comprehensive ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
With Fed Chairman Powell sounding a more dovish tone, U.S. interest rates are likely to increase at a slower rate than previously anticipated. This shift will benefit companies that earn a significant portion of their revenues outside the U.S., like the big pharma names mentioned above.